These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 18393001)
1. The European approach to in-transit melanoma lesions. Hoekstra HJ Int J Hyperthermia; 2008 May; 24(3):227-37. PubMed ID: 18393001 [TBL] [Abstract][Full Text] [Related]
2. Current status of hyperthermic limb perfusion for in-transit melanoma. Ross MI Int J Hyperthermia; 2008 May; 24(3):205-17. PubMed ID: 18392999 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498 [TBL] [Abstract][Full Text] [Related]
8. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234 [TBL] [Abstract][Full Text] [Related]
9. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis. Di Filippo F; Rossi CR; Santinami M; Cavaliere F; Garinei R; Anzà M; Perri P; Botti C; Di Angelo P; Pasqualoni R; Di Filippo S In Vivo; 2006; 20(6A):739-42. PubMed ID: 17203758 [TBL] [Abstract][Full Text] [Related]
10. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS; J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537 [TBL] [Abstract][Full Text] [Related]
11. Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha. Deroose JP; Eggermont AM; van Geel AN; Verhoef C Curr Opin Oncol; 2011 Mar; 23(2):183-8. PubMed ID: 21150602 [TBL] [Abstract][Full Text] [Related]
13. Isolated limb perfusion for melanoma patients--a review of its indications and the role of tumour necrosis factor-alpha. Grünhagen DJ; de Wilt JH; van Geel AN; Eggermont AM Eur J Surg Oncol; 2006 May; 32(4):371-80. PubMed ID: 16520016 [TBL] [Abstract][Full Text] [Related]
14. Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion. Testori A; Verhoef C; Kroon HM; Pennacchioli E; Faries MB; Eggermont AM; Thompson JF J Surg Oncol; 2011 Sep; 104(4):397-404. PubMed ID: 21858835 [TBL] [Abstract][Full Text] [Related]
15. The use of isolated limb perfusion to manage recurrent malignant melanoma. Ma D; Ariyan S Clin Plast Surg; 2000 Jul; 27(3):441-50, ix. PubMed ID: 10941564 [TBL] [Abstract][Full Text] [Related]
16. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion. Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605 [TBL] [Abstract][Full Text] [Related]
17. Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma. Noorda EM; Takkenberg B; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Hart GA; Kroon BB Ann Surg Oncol; 2004 May; 11(5):491-9. PubMed ID: 15078633 [TBL] [Abstract][Full Text] [Related]
18. Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion. Di Filippo F; Giacomini P; Rossi CR; Santinami M; Anzà M; Garinei R; Perri P; Botti C; Di Angelo P; Sofra C; Pasqualoni R; Sperduti I; Cavaliere F; Di Filippo S; Corrias F; Armenti A; Ferraresi V; Ginebri A In Vivo; 2009; 23(2):347-52. PubMed ID: 19414425 [TBL] [Abstract][Full Text] [Related]
20. Hyperthermic antiblastic perfusion with TNFalpha and melphalan in stage III limb melanoma patients: A phase I - II SITILO study. Di Filippo F; Rossi CR; Garinei R; Anzà M; Cavaliere F; Botti C; Perri P; Di Filippo S; Di Angelo P; Principi F; Laurenzi L J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):97-101. PubMed ID: 16767914 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]